Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously
25.11.2022 09:00:00 EET | Business Wire | Press release
Regulatory News:
Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation to advocate people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help from their physician.
“We are pleased to join our patients, healthcare professionals and partners in supporting Iron Deficiency Day 2022, a call for people around the world to get informed and to understand what can happen when iron levels are not properly managed,” said Hervé Gisserot, General Manager of CSL Vifor. “We are dedicated to building awareness of iron deficiency and iron deficiency anemia, to help patients understand their symptoms, improve access and ultimately receive appropriate treatment.”
Iron deficiency and iron deficiency anemia affect one in every two chronic heart failure patients 2,3 and is associated with reduced quality of life4, reduced exercise capacity and increased risk of hospitalization5. Despite the serious consequences and high prevalence of iron deficiency, the condition remains under-recognized6.
The importance of iron for the health of heart failure patients was recently highlighted in the new whitepaper “Heart Failure, an inconvenient truth” which advocates for an extension of current heart failure management strategies to include and increasingly focus on improving quality of life. This includes early diagnosis and treatment of iron deficiency.
“Iron deficiency is a highly prevalent and serious condition among heart failure patients and has a significant impact on their quality of life,”, said Steven Macari, President of AVEC France and co-author of Heart Failure, an inconvenient truth. “It is easily diagnosed and treatable, yet many primary care professionals often overlook symptoms of iron deficiency like fatigue and breathlessness as expected comorbidities of heart failure, and it is often the proactive empowered patient who informs and suggests to be tested. It is therefore vital that we inform practitioners around the importance of diagnosing and treating iron deficiency in patients at risk, and that patient organizations inform their members.”
To learn more about the importance of early diagnosis and recognizing symptoms of iron deficiency, visit www.takeironseriously.com/check-your-symptoms . Use hashtags #TakeIronSeriously and #IDDay2022 on Twitter and LinkedIn.
Iron Deficiency Day is endorsed by multiple international organizations in the United Kingdom, Ireland, Romania, Greece, Saudi Arabia, Russia and for the first time in Slovakia.
About “Heart Failure, an inconvenient truth”
The whitepaper “Heart Failure, an inconvenient truth” is based on a pan-European survey among more than 600 heart failure patients and has been developed together with Pumping Marvellous (UK), AVEC (FR), Herzschwäche Deutschland (DE), The Patients Voice (NL), and Vintura. The aim of the paper, which was funded by CSL Vifor, is to advocate for a better quality of life in heart failure. It can be downloaded here: (https://www.viforpharma.com/sites/vifor-corp/files/White%20paper%20_heart%20failure_V10.2_Digital.pdf)
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
Notes to Editors
Takeironseriously.com is intended to provide educational information to an international audience outside the US; it is available in 14 languages. All information on the site is intended for educational purposes only and should not be used to replace a discussion with a healthcare professional. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
About iron deficiency
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide7, yet despite the serious consequences and high prevalence8, it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five9. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being10. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality10. Common symptoms include fatigue10, 12, 13 pale skin12, brittle nails12, 14, craving non-food items such as dirt, clay and ice15, and an inability to concentrate10, 16. In children, iron deficiency can significantly impair cognitive and motor development17.
The World Health Organization has published new guidelines to help the detection of iron deficiency and iron overload. These guidelines provide global, evidence-informed recommendations on the use of indicators for assessing iron status and application of the use of ferritin concentrations, an indicator of iron storage. Find more here: https://www.who.int/publications/i/item/9789240000124
References
- Hassan, Tamer Hasan et al. “Impact of Iron Deficiency Anemia on the Function of the Immune System in Children.” Ed. Esaki M. Shankar. Medicine 95.47 (2016): e5395. PMC. Web. 12 June 2018.
- Ebner N, von Haehling S. Iron deficiency in heart failure: a practical guide. Nutrients. 2013;5(9):3730-9. doi:10.3390/nu5093730.
- Klip IT, Comin-Colet J, Voors A a, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017.
- Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
- Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
- Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
- Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
- World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
- Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
- Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
- Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
- Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
- Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
- Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
- Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
- Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
- World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005079/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HY10 Selected Among the First Participants for Visa’s Infinite Private Program14.7.2026 22:46:00 EEST | Press release
HY10, the first financial and lifestyle platform built for globally mobile ultra and high-net-worth individuals, today announced it is among the first businesses selected to participate in Visa's Infinite Private program. Unveiled at the Visa Payments Forum (VPF) in Paris, the launch brings together unlimited-spend payment cards, concierge and lifestyle services into a single integrated platform, powered by Visa's trusted global payments network. The announcement comes as more than 2,000 leaders from banks, fintechs and payment providers gather at Visa Payments Forum to explore the future of commerce and premium financial services. HY10's participation underscores its position at the forefront of premium financial experiences for globally mobile entrepreneurs, investors and families. "Private banking hasn't fundamentally evolved for decades," said Erekle Tokhosashvili, Co-Founder of HY10. "The world's wealthiest individuals are still forced to piece together multiple providers for bank
L&T Technology Services Partners with Anthropic to Deliver AI-Powered Engineering Intelligence for Products and Manufacturing14.7.2026 18:28:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale. Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained. By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, A
Presidio Investors Announces Sale of ElevATE Semiconductor to Diodes Incorporated14.7.2026 17:56:00 EEST | Press release
Presidio Investors (“Presidio”), a lower middle market private equity firm, today announced that it has entered into a definitive agreement to sell ElevATE Semiconductor, Inc. (“ElevATE”) to Diodes Incorporated (Nasdaq: DIOD) in an all-cash transaction valued at $250 million. ElevATE, headquartered in San Diego, California, is a leading fabless designer of low-power, high-density integrated circuits for the automated test equipment (ATE) industry. The sale marks the successful realization of Presidio’s first continuation fund, which was formed in 2023 to extend the firm’s partnership with ElevATE and support the company’s next phase of growth. The acquisition of ElevATE by a leading global semiconductor company validates the strategy behind the continuation vehicle and delivers a strong outcome for the company, its employees, and Presidio’s investors. Presidio first invested in ElevATE in 2018, when the company was a small, founder-led team of analog chip designers serving the ATE mark
Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut14.7.2026 17:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition are heading to the 2026 Experimental Aircraft Association (EAA) AirVenture in Oshkosh, Wisconsin. Both aircraft will be on display for the first time at the show alongside a broad lineup of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714774354/en/ Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut “EAA AirVenture is one of the most important opportunities each year for us to connect with customers and the broader aviation community,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Being on the ground in Oshkosh allows us to showcase the breadth of our portfolio. Events like AirVenture also give us valuable face-to-face time to better understand how our customers operate and
Clearlake Capital Announces Partnership with Databricks to Advance AI-Enabled Investing and Portfolio Value Creation14.7.2026 17:00:00 EEST | Press release
Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities. Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage. “Data and A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
